Boyar Asset Management Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,990 shares of the company’s stock after selling 199 shares during the period. Johnson & Johnson makes up about 2.7% of Boyar Asset Management Inc.’s holdings, making the stock its 10th largest holding. Boyar Asset Management Inc.’s holdings in Johnson & Johnson were worth $3,355,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after buying an additional 2,815,655 shares during the period. State Street Corp lifted its stake in Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after purchasing an additional 803,013 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 3.3% during the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after purchasing an additional 805,831 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after purchasing an additional 328,297 shares during the last quarter. Finally, California Public Employees Retirement System lifted its stake in Johnson & Johnson by 2.7% during the third quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock worth $1,919,726,000 after purchasing an additional 310,473 shares during the last quarter. 67.94% of the stock is owned by institutional investors.
Johnson & Johnson Stock Up 0.3 %
Shares of NYSE:JNJ opened at $158.91 on Monday. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $183.35. The firm has a market capitalization of $412.96 billion, a P/E ratio of 33.24, a P/E/G ratio of 2.71 and a beta of 0.53. The stock has a 50 day moving average price of $159.70 and a 200-day moving average price of $166.20. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a dividend yield of 3.00%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is presently 94.56%.
Insider Buying and Selling
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.20% of the stock is currently owned by company insiders.
Analyst Ratings Changes
JNJ has been the subject of several research analyst reports. UBS Group initiated coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target for the company. Guggenheim started coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. Morgan Stanley lifted their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. Piper Sandler decreased their price objective on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, Credit Suisse Group lifted their price objective on Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $173.00.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Warren Buffett Boosts Occidental Stake, Adds 3.46 Million Shares
- What’s Behind The Recent Meteoric Rise Of Tingo Group
- Is PulteGroup Overbought After Double-Digit Gains?
- Netflix Stock Just Had Its Largest Intraday Gain Since 2022
- Analyst Flags Concerns About P&G Growth Despite Earnings Beat
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.